==== Front Cancer Manag ResCancer Manag ResCancer Management and ResearchCancer Management and Research1179-1322Dove Medical Press 10.2147/CMAR.S167424cmar-10-2325ReviewTargeting energy metabolism to eliminate cancer cells Shahruzaman Shazwin Hani Fakurazi Sharida Maniam Sandra Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor Darul Ehsan, Malaysia, sandra@upm.edu.myCorrespondence: Sandra Maniam, Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor Darul Ehsan, Malaysia, Tel +60 3 89 47 2322, Email sandra@upm.edu.my2018 31 7 2018 10 2325 2335 © 2018 Shahruzaman et al. This work is published and licensed by Dove Medical Press Limited2018The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.Adaptive metabolic responses toward a low oxygen environment are essential to maintain rapid proliferation and are relevant for tumorigenesis. Reprogramming of core metabolism in tumors confers a selective growth advantage such as the ability to evade apoptosis and/or enhance cell proliferation and promotes tumor growth and progression. One of the mechanisms that contributes to tumor growth is the impairment of cancer cell metabolism. In this review, we outline the small-molecule inhibitors identified over the past decade in targeting cancer cell metabolism and the usage of some of these molecules in clinical trials. Keywords cancer metabolismhypoxiaglycolysisoxidative phosphorylation ==== Body Introduction Cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer-related deaths reported in 2012.1 It is a major disease burden worldwide and will be a prominent health issue globally. The inability of cells to respond to stress and to repair damage underlies many forms of cancer. Lung, liver, stomach, and bowel cancers are the most common causes of cancer death worldwide, accounting for nearly half of all cancer death. Lung and breast cancers were reported as the most common cancers diagnosed in men and women, respectively.2 Interestingly, in more developed countries (as defined by the United Nations which includes all regions of Europe, Northern America, Australia/New Zealand, and Japan), prostate and lung cancers are the leading cause of cancer death in men and women, respectively.2 The regional imparity in the mix of cancers is driven largely by the availability of improved treatment and technological progress in early detection of tumor.3 Cancer is also regarded differently in different settings, by which in high-income countries, it is regarded as a preventable and often curable disease. However, in many low- and middle-income countries, it is regarded as a painful death sentence. According to the World Health Organization, it is expected that the number of annual new cases to rise by 70% for the next 20 years. Past research has identified many oncogenes and tumor suppressors that are frequently altered in human tumors. These altered genes affect key signaling pathways that govern the cell cycle and thus have the potential to be therapeutic targets. Multiple classes of chemotherapy drugs are used, mainly in combination, to target cancer cells more effectively. In recent years, it has become apparent that differences in the genetic background of cancer patients result in varying responses to chemotherapy. This has led to an increased research focus on pharmacogenomics. Cancer pharmacogenomics relates to the study of germline genetic variants that contribute to a chemotherapy-induced phenotype.4 A fundamental characteristic of cancer cells is their ability to sustain indefinite cycles of proliferation by deregulating the release of growth signals. Growth-promoting signals govern entry and progression of cells through the cell cycle, thereby ensuring the homeostasis of cell number and maintenance of normal tissue architecture and function. In 2000, Hanahan and Weinberg outlined the acquired capability of “hallmarks of cancer,” which includes the ability to sustain growth signals, avoid growth suppressors, invade and metastasize to other tissues, induce angiogenesis, resist cell death, and proliferate indefinitely.5 In 2011, these hallmarks were updated to include the ability of cancer cells to maintain the tumor microenvironment.6 Among the ways, cancer cells achieve this by metabolic reprogramming that involves altering energy metabolism in order to fuel their growth and division.6 Mitochondria have long been recognized as the powerhouses of the cell and have recently received recognition as a potential target for therapeutic intervention of cancer. In contrast to normal undifferentiated cells, which mainly rely on oxidative phosphorylation (OXPHOS) to produce energy for cellular processes, cancer cells in the hypoxic microenvironment rely on glycolysis as their primary energy source. The phenomenon in which cancer cells preferentially use glycolysis to metabolize glucose in the presence of oxygen was identified by Otto Warburg and was later known as aerobic glycolysis. At that time, Warburg hypothesized that the switch to energy production by glycolysis in cancer cells was due to irreversible mitochondrial damage leading to permanent impairment of aerobic respiration.7 However, this hypothesis was disputed as most cancer cells retain functional mitochondria. Although aerobic glycolysis is often found in malignant tumors, OXPHOS still contributes to energy production in cancers and may play a major role in energy production in some cancers.8 Nonetheless, the “Warburg effect” is one of the best studied metabolic phenotype of cancer cells. In this review, we focus on the research conducted over the past decade in identifying potential therapeutic targets of cell metabolism mainly in cancer. We summarize published in vivo, in vitro, and clinical studies of new evidences and novel small molecules that have implications in regulating cancer cell metabolism. The OXPHOS system in mitochondria Functionally, mitochondria are the key players in cellular adenosine triphosphate (ATP) production, fatty acid oxidation, heme biosynthesis, apoptosis induction, heat generation, and calcium homeostasis. Mitochondria are best known for their role in ATP production, which is performed via OXPHOS. The mitochondrial OXPHOS system is embedded in the mitochondrial inner membrane (MIM) and represents the final step in the conversion of nutrients to energy by catalyzing the generation of ATP. Carbon fuels are oxidized in the citric cycle to yield high-energy electrons.9 This electron motive force is converted into a proton motive force, and this, in turn, is converted into a phosphoryl transfer potential. The flow of electrons from nicotinamide adenine dinucleotide (NADH) or flavin adenine dinucleotide (FADH) to oxygen through protein complexes located in the MIM leads to the pumping of protons out of the matrix. The resulting uneven distribution of protons generates a pH gradient and trans-membrane electrical potential that creates the proton motive force. ATP is synthesized when protons flow back to the mitochondrial matrix through ATP synthase (complex V).10 The membrane potential is essential for other mitochondrial functions such as mitochondrial protein import and is used to trigger molecular changes that alter mitochondrial behavior in response to mitochondrial dysfunction.9 Induction of cell death is influenced by changes in the amount of ATP generated by the mitochondria, and this death may occur in various ways depending on the level of ATP in the cell. In several cell types, it has been shown that a change in the amount of ATP production is sufficient in itself to initiate apoptosis.10,11 The intrinsic apoptotic pathway is initiated following the activation of caspase-9, which requires Apaf-1. In the absence of apoptotic stimuli, Apaf-1 exists in a monomeric form. In response to apoptotic stimuli, cytochrome c activates Apaf-1 by binding to its C-terminus. Concurrently, ATP bound to the ATPase domain of Apaf-1 is hydrolyzed, and this promotes Apaf-1 oligomerization. Interestingly, Izyumov et al reported a two-third decrease of the initial intracellular ATP level in HeLa cells, which was achieved by using 2-deoxyglucose (DOG) and OXPHOS inhibitors, and was found to induce apoptosis.12 In contrast, a severe depletion of ATP (>70%) using staurosporine (protein kinase inhibitor) in human T cells resulted in a switch in response of cells to typical apoptotic stimuli from apoptosis to necrosis.12 Collectively, these data suggest that cell death is elicited under a compromised ATP level. Apoptosis inactivates PARP-1, whereas necrosis causes PARP-1 overactivation, which consumes large amount of NAD+ resulting in massive ATP depletion.10,13 Perhaps modulating in vivo ATP availability might be an important strategy in inducing cell death and preventing tumor growth and progression. OXPHOS as a therapeutic target Aerobic glycolysis has long been accepted as one of the pathways utilized by proliferative cancer cells to meet their bioenergetics demand, which is essential in tumorigenesis. Elevated mitochondria-derived reactive oxygen species (ROS), a by-product of electron transport chain activity, regulate both tumor cell proliferation and quiescence and promote metastasis14 and genomic instability.15 This review discusses on the current small-molecule inhibitors, typically less than 900 Da16 that are developed to target the mitochondrial OXPHOS in cancer cells (Table 1). Uncouplers transport protons into mitochondrial matrix via ATP-synthase-independent pathway. Hence, this reduces the proton motive force across the MIM and decreases the mitochondrial ROS production. Mitochondrial uncouplers such as FCCP not only inhibit mitochondrial membrane potential but may also affect the membrane potential and cell volume.17 Kenwood et al reported a bona fide mitochondria uncoupler, BAM15 that has preference for protonophore activity at the mitochondria but not at the plasma membrane. The exact mechanism of BAM15 remains unclear. However, BAM15 was capable in increasing mitochondrial respiration in the presence of an ATP synthase inhibitor, providing evidence of BAM15 as a mitochondrial uncoupler.18 It was suggested that the effect is due to the structural preference of BAM15 for the lipid composition of the inner mitochondrial membrane.18 A high-throughput screening of small-molecule library using luciferase-driven hypoxia-inducible factor (HIF)-1 reporter HCT116 cells under hypoxic condition led to the identification of BAY 87-2243. BAY 87-2243, a class of aminoalkyl-substituted compounds, was initially found to inhibit HIF-1α and HIF-2α protein accumulation without affecting HIF target gene expression levels.17 Further investigations revealed that BAY 87-2243 inhibited in vitro and in vivo mitochondrial complex I activity which prevented ROS-mediated HIF-1 inhibition.19,20 It was also noted that BAY 87-2243 restored prolyl hydroxylase enzyme activity, a negative regulator of HIF-1, and thus, a reduced level of HIF-1 was observed.19 Combination of B-RAF inhibitor that upregulates OXPHOS and BAY 87-2243 was shown to induce augmented tumor regression in nude mice-bearing B-RAF mutant melanoma xenografts.20 This evidence provides a promising future for combination of targeted therapies to prevent resistance to either agent. A biochemical absorbance-based high-throughput study was used to identify the small-molecule inhibitor of complex IV in mitochondrial extracts. The current available complex IV inhibitors either bind to the allosteric site18 or inhibit the copper-dependent activity21 within complex IV, which disrupts the electron transport chain. Tissues with high dependence on aerobic respiration, such as the central nervous system and heart, are affected upon treatment with these inhibitors. ADDA, 5(1-[2-(1-adamantyl)ethoxy]-3-(3,4-dihydro-2(1H)-isoquinolinyl)-2-propanol hydrochloride]), was found to possess a significant in vitro and mouse xenograft model (nude mouse, rear flank) antiglioblastoma multiforme activity by specifically noncompetitively inhibiting complex IV activity.22 Of note, chemoresistance to temozolomide in glioblastoma multiforme is associated with an increased level of complex IV activity.23 Glycolysis Both normal and cancer cells utilize glucose and glutamine as sources of energy and also for biosynthesis of macromolecules. The high rate of glucose metabolism in cancer cells is facilitated by an increase in glucose transport by one or more isoenzymes of the glucose transporters (GLUT 1–4).19 Glucose molecules are phosphorylated by hexokinases to form glucose-6-phosphate. Glucose-6-phosphate will either generate pyruvate or be fed into the pentose phosphate pathway (PPP) to generate ribose-5-phosphate and nicotinamide adenine dinucleotide phosphate (NADPH). Glutamine, on the other hand, is converted into glutamate in the cytosol by the enzyme glutaminase-1. Glutamate is then transported to the mitochondria, where it is converted into α-ketoglutarate. α-Ketoglutarate that enters the tricarboxylic acid (TCA) cycle results in the generation of malate and citrate. Glutamine serves as a source of carbon to replenish the TCA cycle, produces glutathione, and is a precursor to nucleotide and lipid synthesis via reductive carboxylation.24 The inappropriate proliferation of cancer cells requires high energy, and the cells generate ATP to satisfy the biomass production. The enhanced glycolytic rate in cancer cells is required not only to meet the need for energy but also to maintain the level of glycolytic intermediates needed for biosynthesis of macromolecules. The biosynthetic activities required for proliferating cancer cells involve high rates of nucleotide synthesis, amino acid synthesis, and lipogenesis. Glycolysis provides essential molecules for both nucleotide and amino acid syntheses. The PPP consists of the oxidative generation of NADPH and nucleotide biosynthesis. The oxidation of glucose-6-phosphate generates NADPH, and the non-oxidative interconversion of phosphorylated sugars is required for nucleotide biosynthesis. Glycolysis inhibitors The accelerated glycolysis rate in cancer cells is associated with the overexpression of pathway enzymes, transporters, and isoenzymes with different regulatory properties.25 Interestingly, overexpression of glycolytic enzymes was noted in almost 70% of human cancers.26 The key enzymes involved in glycolysis are hexokinase, phosphofructokinase, and pyruvate kinase (PK). Inhibition of glycolysis severely impairs the ATP generation and renders cancer cells to be highly dependent on this metabolic pathway for survival. Table 2 depicts small-molecule inhibitors of glycolysis along with their mechanisms emphasized on current molecular targets. The generation of pyruvate is an important metabolic control point in cellular metabolism as it can be converted to either lactate and NAD+ by lactate dehydrogenase A (LDHA), which is important for continuation of glycolysis, or acetyl coenzyme A (CoA) by pyruvate dehydrogenase (PDH) for entry to glycolysis and mitochondrial respiration. NADH-competitive selective inhibitor of LDHA, quinolone-3-sulfonamide, was developed through high-throughput screening and leads optimization.27 However, this compound was reported to possess an unacceptable pharmacokinetic profile that prevents it to be further investigated in in vivo models.27 Acetyl CoA is involved in the synthesis of several lipid building blocks, which includes mevalonate. Protein farnesylation and geranylgeranylation are collectively known as prenylation, a lipid posttranslational modification that facilitates cell membrane anchoring and is required for oncoprotein transformation.28 Statins are lipid-lowering drugs that block cholesterol biosynthesis by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in the mevalonate pathway.27 The role of statins in modulating the mevalonate pathway to exert the anticancer activity was reported as early as 2005.29 In a recent study, mevalonate inhibitors, pitavatstatin and zolendronic acid, synergistically prevented geranylgeranylation, which resulted in inducing apoptosis in a panel of ovarian cancer cell lines.30 Simvastatin exerted an antiproliferative effect in renal cancer cells through cholesterol deprivation and prenylation-associated mechanisms.31 AZD3965 is a potent selective inhibitor of monocarboxylate transporter 1 (MCT1) found in cell lines displaying MCT1 and shows higher sensitivity in hypoxia.32 Recent studies have demonstrated that AZD3965 inhibits lactate transport and cell growth in cancer cells which lack MCT4 protein.32–34 AZD3965 is currently tested in Phase I clinical trial. The most promising drug-targeting cancer cell metabolism to date is 3-bromopyruvate, which was first discovered in the 1960s, but its anticancer properties were discovered in 2001.15 3-Bromopyruvate, an alkylating agent, is a broad-spectrum inhibitor of multiple metabolic enzymes. It was shown to dampen ATP generation and inhibits multiple metabolic targets such as hexokinase 2 (HK 2), 3-phosphoglycerate kinase (PGK), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), lactate dehydrogenase (LDH), pyruvate dehydrogenase complex (PDC), succinate dehydrogenase (SDH), α-ketoglutarate dehydrogenase, isocitrate dehydrogenase (IDH), glyoxalases 1 and 2, and serine hydroxyethyltransferase.35–39 Currently, no clinical trials have been approved for 3-bromopyruvate even though two reports have already appeared describing the use of this inhibitor in volunteer patients with cancer.40,41 Small-molecule activators of glycolysis PK is a rate-limiting glycolytic enzyme that catalyzes the final step of glycolysis, which produces pyruvate and ATP.42 PK muscle isozyme, PKM2, is expressed in tissues with anabolic functions and is found both in cancer and in normal tissues. In the majority of cancer cells, the expression of PKM2 is increased, which suggests that PKM2 may be an attractive target for cancer therapy.43 PKM2 is expressed in essentially all human cancers, and efforts have been made to use PKM2 as a cancer biomarker.44 ML265 is a potent PKM2 activator that significantly reduces the tumor size in 7-week mouse xenograft without showing signs of acute toxicity.45 ML265 was found to activate PKM2 in pervanadate-treated cells, a condition known to inhibit PKM2 activity through accumulation of phosphotyrosine peptides.45 ML285, another small-molecule activator of PKM2, was found to reduce the shunt of glucose through the PPP. This sequentially allows the synthesis of NADPH, which is needed for generating reduced glutathione and required for ROS detoxification. ML285 protects the enzyme from oxidation by ROS and results in sensitization to oxidative stress and increased apoptosis.46 Activation of PKM2 promotes tumor suppression in tumor growth in vivo.47–49 PA-12 stimulates the PK activity of recombinant PKM2 and effectively suppresses both anchorage-dependent and anchorage-independent growth of lung cancer cells in the nonessential amino acid-depleted medium.50 Activation of AMP-activated protein kinase (AMPK) is required to facilitate the oxidative metabolism of non-glucose substrates, specially glutamine and lactate, to maintain cell survival. BL-AD008, a small-molecule activator of AMPK/ZIPK, showed antiproliferative activities toward cervical cancer cells. It induced apoptosis by targeting AMPK/ZIPK in cervical cancer.51 AMPK direct activator MT 63-78 exerted growth inhibitory effects in prostate cancer cells in vitro as well as in xenograft models by lipogenesis inhibition.52 Table 3 shows the lists of small-molecule activators in glycolysis. Hypoxia targeting small-molecule inhibitors Adaptive metabolic response toward a low oxygen environment is essential to maintain rapid tumor proliferation and progression.53 The vascular network that surrounds the tumor creates an intermittent hypoxia, which plays a crucial role in cancer development, along with mitochondrial transformation associated with treatment failure.54 When oxygen demand exceeds supply, HIF is switched on.55 HIF is a heterodimer comprising α and β subunits that translocate into the nucleus.56 Mammalian cells respond to hypoxia by implementing changes in gene expression controlled by the hypoxia-inducible factor 1 (HIF-1) transcription factor.57,58 Three different genes have been identified that encode the subunits of HIF: HIF1α, HIF2α, and HIF3α. All three HIFα subunits heterodimerized with HIF-1β subunit are subjected to posttranslational regulations dictated by the oxygen concentration in the environment.59 In hypoxia, HIF-1α heterodimerized with the constitutively expressed HIF-1β [the aryl hydrocarbon receptor nuclear transporter (Arnt)] and translocated to the nucleus, where it bound to hypoxia response elements (HREs) in the promoters of various genes.55 The interaction between HIF-1α and HIF-1β is critical in the process of tumor survival. A hypoxic state is important for tumor growth to start. It is thought that HIF-1 expression (HIF-1α and HIF-1β) controls the initiation of tumor growth and could be important in affecting the antitumor growth by its changing growth to be more malignant in a hypoxic state.60 Therefore, therapeutic targeting of hypoxia in cancer has the potential to improve treatment efficacy. Resistance to therapy in the presence of hypoxia was noted as early as the 1920s, with the first clinical implications observed in tumors in the lung that exhibited resistance to ionizing radiation. Under hypoxic conditions, DNA-damaging free radicals are rapidly reduced, thereby avoiding DNA damage. HIF-1 plays a central role in tumor pathology and is a target for treatment and therapy.61–65 To date, the small-molecule inhibitors that target HIF mainly decrease its protein levels, DNA-binding, or transactivation.66,67 Table 4 lists various small molecules that target the hypoxic microenvironment in cancer. Many different agents that specifically target HIF have been investigated for their role during hypoxia over the past few decades. PX-478 (S-2-amino-3-[4V-N,N,-bis(2-chloroethyl)amino]phenyl propionic acid N-oxide dihydrochloride) is known to suppress constitutive and hypoxia-induced levels of HIF-1α in various cancer cells, which include ovarian, colon, prostate, breast, renal, pancreatic, and lung.68 It was noted to show marked tumor regression and growth delay in tumor xenografts with high level of HIF-1α.69 This HIF-1α suppressor was shown to be selective in lowering HIF-1α and inhibiting its activity in multiple levels.70 PX-478 has completed its Phase I clinical trial as an oral agent in lymphoma and advanced solid tumors. Another small-molecule inhibitor that targets HIF1a is EZN-2968. EZN-2968 is an RNA antagonist composed of locked nucleic acid-based oligonucleotide that specifically binds and inhibits the expression of HIF-1α mRNA.69,70 A pilot study of EZN-2968 in patients with refractory solid tumors showed a reduction in HIF-1α mRNA and its target genes in tumor biopsies.71 Third Phase I clinical trial has been recently initiated in patients with hepatocellular carcinoma to demonstrate the proof of mechanism of EZN-2968. A library of aryloxy acetylaminobenzoic acid scaffold-focused screening followed by lead optimization for the identification of HIF-1α inhibitor resulted in the identification of IDF-11774, which was later shown to inhibit the expression of HIF-1α target genes. IDF-11774 inhibits angiogenesis, suppresses HIF-1α refolding, and stimulates proteosomal-mediated HIF-1α-degradation.72 Additionally, IDF-11774 was shown to decrease the glucose-dependent energy metabolism.72 This promising small-molecule inhibitor modulates both hypoxic regulators and glycolysis to prevent cancer cell growth. Summary and future perspectives Cancer metabolism is one of the oldest areas of research in cancer biology which pioneers from the identification of tumor suppressors and oncogenes. With explosion of research in cancer cell metabolism in the last decade, it is almost impossible to highlight all the findings in one review. In this review, we have discussed the various small molecules that were discovered in the last decade that are involved in cell metabolism, mainly glycolysis, OXPHOS, and hypoxia (Figure 1). The advancement of current technologies especially in high-throughput studies allows rapid identification of compounds with selected and specific targets. The ability of these small molecules to render cell metabolism is supported by the impaired growth of tumor in vivo and/or in vitro. Rewiring metabolism in cancer cells plays a pivotal role in tumor survival, invasion, proliferation, and resistance to anticancer therapies. The use of cell metabolism small-molecule inhibitor in cancer treatment imposes several challenges. Several drugs that impair cell metabolism have demonstrated the modest effect in cancer therapy. This is most likely due to the complexity of the metabolic pathways in cancer. Many pathways and transcriptional factors associated with cancer metabolism are also involved in maintaining the physiological process of the body. For example, the normal tissues of brain, retinae, and testis use glucose as their main energy source. Impairment of glycolysis that limits the glucose supply may potentially be toxic to these tissues. Metabolic plasticity and heterogeneity in cancer cells drive tumor growth, mediate metastasis, and contribute to treatment resistance. Hence, the efficacy of cancer metabolism therapy requires careful evaluation. Inhibiting individual enzymes or blocking single pathways seldom leads to effective cancer treatment. Therefore, the combined approach of targeting cellular metabolism in conjunction with the use of chemotherapeutic drugs may provide a promising strategy to overcome therapeutic resistance and therefore aid in cancer therapy. In conclusion, the concept of cancer metabolism provides more targets for cancer treatment. Undoubtedly, like other targeted therapies being developed, therapies directed to cancer metabolism will be most effective if the orchestrations of metabolic alterations in cancer cells to support growth, proliferation, and differentiation are well understood. Acknowledgments We thank the Universiti Putra Malaysia (Programme Grant: Putra Grant GP-IPM/2014/9445100) for supporting this work. SHS was supported by Graduate Research Fellowship from Universiti Putra Malaysia and MyBrain program from Malaysian Ministry of Higher Education. Disclosure The authors report no conflicts of interest in this work. Figure 1 Summary of metabolic pathways (A–C) and small molecules that modulate these pathways (green). Abbreviation: HIF, hypoxia-inducible factor. Table 1 List of OXPHOS drugs and their functions No. OXPHOS drugs Function Reference 1 Berberine Inhibitor of complex I 73 2 IACS-10759 Inhibitor of complex I 74 3 BAY 87-2243 Inhibitor of complex I 20 4 AG311 Inhibitor of complex I 75 5 Atpenins Inhibitor of complex II 76 6 3-NP Inhibitor of complex II 77 7 DT-010 Inhibitor of complex II 78 8 Rosamine Inhibitor of complex II and ATP synthase activities 79 9 Phenethyl isothiocyanate Inhibitor of complex III 80 10 Tetrathiomolybdate Inhibitor of complex IV 21 11 ADDA 5 Inhibitor of complex IV 22 8 Meclizine Inhibitor of complex V 81 12 Bupivacaine Mitochondrial uncoupler 82 13 FCCP Mitochondrial uncoupler 17 14 BAM 15 Mitochondrial uncoupler 18 Abbreviations: OXPHOS, oxidative phosphorylation; ATP, adenosine triphosphate; 3-NP, 3-nitropropionic acid. Table 2 List of glycolysis drugs and their functions No. Glycolysis drugs Application Reference 1 AZD7545 Inhibit PDK 2 83 2 VER-246608 Inhibit PDK 84 3 6-Aminonicotinamide Inhibit G6PD 85 4 3-Bromopyruvate Inhibit HK 86 5 3PO Small-molecule inhibitor of PFKFB3 87 6 PFK-158 Inhibit PFKFB3 88 7 FX11 Inhibit LHDA 89 9 Quinoline 3-sulfonamides Inhibit LDHA 27 10 Shikonin Inhibit PKM2 90 11 ENO block Inhibit enolase 91 12 Epigallocatechin-3-gallate Inhibit PGM1 92 13 Pitavatstatin and zolendronic acid Inhibit geranylgeranylation 30 14 Simvastatin Inhibit prenylation 31 Abbreviations: 3PO, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; LDHA, lactate dehydrogenase A. Table 3 List of small-molecule activators of glycolysis No. Activator Target Reference 1 ML265 PKM2 45 2 ML285 PKM2 46 3 PA-12 PKM2 50 4 BL-AD008 AMPK/ZIPK 51 5 MT 63-79 Direct AMPK activator 52 6 GSK 621 Direct AMPK activator 93 Abbreviation: AMPK, AMP-activated protein kinase. Table 4 List of HIF drugs and their functions No. HIF drug Application Reference 1 Chetomin Inhibit HIF transcription 94 2 PX-478 Decrease the expression of HIF-1α, VEGF, and GLUT1 68 3 EZN-2208 Decrease the expression of HIF-1α and VEGF 95 4 Aminoflavone Decrease HIF translation 96 5 Bisphenol A Promote degradation of HIF-1α protein 97 6 YC-1 Inhibit HIF-1α activity 98 7 Compound DJ12 Inhibit HIF-1α transcription 99 8 KC7F2 Suppress HIFα protein regulators 100 9 EZN-2968 Inhibit the expression of HIF-1α mRNA 71 10 FM19G11 Inhibit HIFα proteins 101 11 PX-12 Inhibit HIF-1α 102 12 LW6 Inhibit HIF-1α 103 13 Indenopyrazole 21 Inhibit HIF-1α 104 14 IDF-11774 Inhibit HIF-1α 72 15 Glyceollins Inhibit HIF-1α synthesis 105 16 2ME2 Small-molecule inhibitor of HIF-1 106 17 Echinomycin Inhibit HIF-1 DNA binding 107 18 Cryptotanshinone Inhibit HIF-1 activation 108 19 PT2385 HIF-2α antagonist 109 20 PT2399 HIF-2α antagonist 110 Abbreviations: HIF, hypoxia-inducible factor; 2ME2, 2-methoxyestradiol; GLUT1, glucose transporter 1. ==== Refs References 1 Stewart BW Wild CP World Cancer Report 2014 Lyon, France WHO 2014 1 2 2 WHO [webpage on the Internet] Fact Sheets by Cancer 2012 [cited June 2017[ Available from: http://globocan.iarc.fr Accessed June 7, 2018 3 Torre LA Bray F Siegel RL Ferlay J Lortettieulent J Jemal A Global cancer statistics, 2012 CA Cancer J Clin 2015 65 2 87 108 25651787 4 Wheeler HE Maitland ML Dolan ME Cox NJ Ratain MJ Cancer pharmacogenomics: strategies and challenges Nat Rev Genet 2013 14 1 23 34 23183705 5 Hanahan D Weinberg RA The hallmarks of cancer Cell 2000 100 1 57 70 10647931 6 Hanahan D Weinberg RA Hallmarks of cancer: the next generation Cell 2011 144 5 646 674 21376230 7 Warburg O On the origin of cancer cells on the origin of cancer Source Sci New Ser 1956 123 123 309 314 8 Zu XL Guppy M Cancer metabolism: facts, fantasy, and fiction Biochem Biophys Res Commun 2004 313 3 459 465 14697210 9 Nunnari J Suomalainen A Mitochondria: in sickness and in health Cell 2012 148 6 1145 1159 22424226 10 Nicotera P Leist M Ferrando-May E Intracellular ATP, a switch in the decision between apoptosis and necrosis Toxicol Lett 1998 102 103 8 139 142 11 Eguchi Y Shimizu S Tsujimoto Y Intracellular ATP levels determine cell death fate by apoptosis or necrosis Cancer Res 1997 57 10 1835 1840 9157970 12 Izyumov DS Avetisyan AV Pletjushkina OY “Wages of fear”: transient threefold decrease in intracellular ATP level imposes apoptosis Biochim Biophys Acta Bioenerg 2004 1658 1–2 141 147 13 Vaseva AV Marchenko ND Ji K Tsirka SE Holzmann S Moll UM P53 opens the mitochondrial permeability transition pore to trigger necrosis Cell 2012 149 7 1536 1548 22726440 14 Brown NS Bicknell R Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer Breast Cancer Res 2001 3 5 323 327 11597322 15 Sullivan LB Chandel NS Mitochondrial reactive oxygen species and cancer Cancer Metab 2014 2 1 17 25671107 16 Zhao L Ren TH Wang DD Clinical pharmacology considerations in biologics development Acta Pharmacol Sin 2012 33 11 1339 1347 23001474 17 To MS Aromataris EC Castro J Roberts ML Barritt GJ Rychkov GY Mitochondrial uncoupler FCCP activates proton conductance but does not block store-operated Ca2+ current in liver cells Arch Biochem Biophys 2010 495 2 152 158 20060804 18 Kenwood BM Weaver JL Bajwa A Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane Mol Metab 2014 3 2 114 123 24634817 19 Ellinghaus P Heisler I Unterschemmann K BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I Cancer Med 2013 2 5 611 624 24403227 20 Schöckel L Glasauer A Basit F Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth Cancer Metab 2015 3 1 11 26500770 21 Kim KK Abelman S Yano N Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1α in cancer cells Sci Rep 2015 5 14296 26469226 22 Oliva CR Markert T Ross LJ Identification of small molecule inhibitors of human cytochrome c oxidase that target chemoresistant glioma cells J Biol Chem 2016 291 46 24188 24199 27679486 23 Oliva CR Nozell SE Diers A Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain J Biol Chem 2010 285 51 39759 39767 20870728 24 Cluntun AA Lukey MJ Cerione RA Locasale JW Glutamine metabolism in cancer: understanding the heterogeneity Trends Cancer 2017 3 3 169 180 28393116 25 Marín-Hernández A Gallardo-Pérez JC Rodríguez-Enríquez S Encalada R Moreno-Sánchez R Saavedra E Modeling cancer glycolysis Biochim Biophys Acta Bioenerg 2011 1807 6 755 767 26 Altenberg B Greulich KO Genes of glycolysis are ubiquitously over-expressed in 24 cancer classes Genomics 2004 84 6 1014 1020 15533718 27 Billiard J Dennison JB Briand J Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells Cancer Metab 2013 1 1 19 24280423 28 Berndt N Hamilton AD Sebti SM Targeting protein prenylation for cancer therapy Nat Rev Cancer 2011 11 11 775 791 22020205 29 Cafforio P Dammacco F Gernone A Silvestris F Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells Carcinogenesis 2005 26 5 883 891 15705602 30 Abdullah MI Abed MN Richardson A Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells Sci Rep 2017 7 1 8090 28808351 31 Woschek M Kneip N Jurida K Marzi I Relja B Simvastatin reduces cancerogenic potential of renal cancer cells via geranylgeranyl pyrophosphate and mevalonate pathway Nutr Cancer 2016 68 3 420 427 27042994 32 Polański R Hodgkinson CL Fusi A Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer Clin Cancer Res 2014 20 4 926 937 24277449 33 Bola BM Chadwick AL Michopoulos F Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport Mol Cancer Ther 2014 13 12 2805 2816 25281618 34 Doherty JR Yang C Scott KEN Blocking lactate export by inhibiting the myc target MCT1 disables glycolysis and glutathione synthesis Cancer Res 2014 74 3 908 920 24285728 35 Azevedo-Silva J Queirós O Baltazar F The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside J Bioenerg Biomembr 2016 48 4 349 362 27457582 36 Pedersen PL 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective “small molecule” anti-cancer agent taken from labside to bedside: introduction to a special issue J Bioenerg Biomembr 2012 44 1 1 6 22382780 37 Shoshan MC 3-Bromopyruvate: targets and outcomes J Bioenerg Biomembr 2012 44 1 7 15 22298255 38 Jardim-Messeder D Moreira-Pacheco F 3-Bromopyruvic acid inhibits tricarboxylic acid cycle and glutaminolysis in HepG2 cells Anticancer Res 2016 36 5 2233 2241 27127128 39 Paiardini A Tramonti A Schirch D Differential 3-bromopyruvate inhibition of cytosolic and mitochondrial human serine hydroxymethyltransferase isoforms, key enzymes in cancer metabolic reprogramming Biochim Biophys Acta 2016 1864 11 1506 1517 27530298 40 El Sayed SM Baghdadi H Zolaly M Almaramhy HH Ayat M Donki JG The promising anticancer drug 3-bromopyruvate is metabolized through glutathione conjugation which affects chemoresistance and clinical practice: an evidence-based view Med Hypotheses 2017 100 67 77 28236852 41 Ko YH Verhoeven HA Lee MJ Corbin DJ Vogl TJ Pedersen PL A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside J Bioenerg Biomembr 2012 44 1 163 170 22328020 42 Israelsen WJ Vander Heiden MG Pyruvate kinase: function, regulation and role in cancer Semin Cell Dev Biol 2015 43 43 51 26277545 43 Dong G Mao Q Xia W PKM2 and cancer: the function of PKM2 beyond glycolysis (review) Oncol Lett 2016 11 3 1980 1986 26998110 44 Mazurek S Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells Int J Biochem Cell Biol 2011 43 7 969 980 20156581 45 Walsh MJ Brimacombe KR Anastasiou D database on the Internet ML265: A Potent PKM2 Activator Induces Tetramerization and Reduces Tumor Formation and Size in a Mouse Xenograft Model 2010 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23905203 Accessed June 7, 2018 46 Brimacombe KR Anastasiou D Hong BS ML285 affects reactive oxygen species’ inhibition of pyruvate kinase M2 Probe Reports from the NIH Molecular Libraries Program 50 Bethesda, MD National Center for Biotechnology Information (US) 2010 1 18 47 Anastasiou D Yu Y Israelsen WJ Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis Nat Chem Biol 2012 8 10 839 847 22922757 48 Kung C Hixon J Choe S Small molecule activation of pkm2 in cancer cells induces serine auxotrophy Chem Biol 2012 19 9 1187 1198 22999886 49 Parnell KM Foulks JM Nix RN Pharmacologic activation of PKM2 slows lung tumor xenograft growth Mol Cancer Ther 2013 12 8 1453 1460 23720766 50 Kim DJ Park YS Kim ND A novel pyruvate kinase M2 activator compound that suppresses lung cancer cell viability under hypoxia Mol Cells 2015 38 4 373 379 25813626 51 Fu L Zhang S Zhang L Systems biology network-based discovery of a small molecule activator BL-AD008 targeting AMPK/ZIPK and inducing apoptosis in cervical cancer Oncotarget 2015 6 10 8071 8088 25797270 52 Zadra G Photopoulos C Tyekucheva S A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis EMBO Mol Med 2014 6 4 519 538 24497570 53 McDonald PC Chafe SC Dedhar S Overcoming hypoxia-mediated tumor progression: combinatorial approaches targeting pH regulation, angiogenesis and immune dysfunction Front Cell Dev Biol 2016 4 27 27066484 54 Tang C Yu J Hypoxia-inducible factor-1 as a therapeutic target in cancer J Gastroenterol Hepatol 2013 28 3 401 405 23173651 55 Cavadas MA Nguyen LK Cheong A Hypoxia-inducible factor (HIF) network: insights from mathematical models Cell Commun Signal 2013 11 1 42 23758895 56 Peng G Liu Y Hypoxia-inducible factors in cancer stem cells and inflammation Trends Pharmacol Sci 2015 36 6 374 383 25857287 57 Shen C Nettleton D Jiang M Kim SK Powell-Coffman JA Roles of the HIF-1 hypoxia-inducible factor during hypoxia response in Caenorhabditis elegans J Biol Chem 2005 280 21 20580 20588 15781453 58 Majmundar AJ Wong WJ Simon MC Hypoxia-inducible factors and the response to hypoxic stress Mol Cell 2010 40 2 294 309 20965423 59 Dengler VL Galbraith MD Espinosa JM Transcriptional regulation by hypoxia inducible factors Crit Rev Biochem Mol Biol 2015 49 1 1 15 60 Choi SH Chung AR Kang W Silencing of hypoxia-inducible factor-1β induces anti-tumor effects in hepatoma cell lines under tumor hypoxia PLoS One 2014 9 7 e103304 25068796 61 Tsai Y-P Wu K-J Hypoxia-regulated target genes implicated in tumor metastasis J Biomed Sci 2012 19 1 102 23241400 62 Ward C Langdon SP Mullen P New strategies for targeting the hypoxic tumour microenvironment in breast cancer Cancer Treat Rev 2013 39 2 171 179 23063837 63 Hu F Shi L Mu R Hypoxia-inducible factor-1α and interleukin 33 form a regulatory circuit to perpetuate the inflammation in rheumatoid arthritis PLoS One 2013 8 8 8 14 64 Li G Lu W Wu X Admission hypoxia-inducible factor 1α levels and in-hospital mortality in patients with acute decompensated heart failure BMC Cardiovasc Disord 2015 15 79 26223692 65 Shen H Maki CG Pharmacologic activation of p53 by small-molecule MDM2 antagonists Curr Pharm Des 2011 17 6 560 568 21391906 66 Devine T Dai M-S Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy Curr Pharm Des 2013 19 18 3248 3262 23151129 67 Welsh S Williams R Kirkpatrick L Paine-Murrieta G Powis G Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha Mol Cancer Ther 2004 3 3 233 244 15026543 68 Koh MY Spivak-Kroizman T Venturini S Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1 Mol Cancer Ther 2008 7 1 90 100 18202012 69 Greenberger LM Horak ID Filpula D A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth Mol Cancer Ther 2008 7 11 3598 3608 18974394 70 Borsi E Perrone G Terragna C Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma Oncotarget 2014 5 7 1779 1792 24732040 71 Jeong W Rapisarda A Park SR Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors Cancer Chemother Pharmacol 2014 73 2 343 348 24292632 72 Ban HS Kim BK Lee H The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth Cell Death Dis 2017 8 6 e2843 28569777 73 Turner N Li JY Gosby A Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate amp-activated protein kinase and improve insulin action Diabetes 2008 57 5 1414 1418 18285556 74 Protopopova M Madhavi B Jennifer B IACS-10759: a novel OXPHOS inhibitor which selectively kill tumors with metabolic vulnerabilities Cancer Res 2015 75 4380 75 Bastian A Matsuzaki S Humphries KM AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1α stabilization Cancer Lett 2017 388 149 157 27939695 76 Miyadera H Shiomi K Ui H Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase) Proc Natl Acad Sci U S A 2003 100 2 473 477 12515859 77 Huang LS Sun G Cobessi D 3-Nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme J Biol Chem 2006 281 9 5965 5972 16371358 78 Wang L Zhang X Cui G A novel agent exerts antitumor activity in breast cancer cells by targeting mitochondrial complex II Oncotarget 2016 7 22 1 11 26700963 79 Lim SH Wu L Kiew LV Chung LY Burgess K Lee HB Rosamines targeting the cancer oxidative phosphorylation pathway PLoS One 2014 9 3 e82934 24622277 80 Xiao D Powolny AA Moura MB Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells J Biol Chem 2010 285 34 26558 26569 20571029 81 Gohil VM Sheth SA Nilsson R Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis Nat Biotechnol 2010 28 3 249 255 20160716 82 Cela O Piccoli C Scrima R Bupivacaine uncouples the mitochondrial oxidative phosphorylation, inhibits respiratory chain complexes I and III and enhances ROS production: results of a study on cell cultures Mitochondrion 2010 10 5 487 496 20546950 83 Morrell JA Orme J Butlin RJ Roche TE Mayers RM Kilgour E AZD7545 is a selective inhibitor of pyruvate dehydrogenase kinase 2 Biochem Soc Trans 2003 31 Pt 6 1168 1170 14641019 84 Moore JD Staniszewska A Shaw T VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells Oncotarget 2014 5 24 12862 12876 25404640 85 Varshney R Dwarakanath BS Jain V Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells Int J Radiat Biol 2005 81 5 397 408 16076755 86 Ganapathy-Kanniappan S Kunjithapatham R Geschwind JF Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting Anticancer Res 2013 33 1 13 20 23267123 87 Clem B Telang S Clem A Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth Mol Cancer Ther 2008 7 1 110 120 18202014 88 Telang S O’Neal J Tapolsky G Identification of a PFKFB3 inhibitor suitable for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib Cancer Metab 2014 2 Suppl 1 14 25215185 89 Le A Cooper CR Gouw AM Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression Proc Natl Acad Sci U S A 2010 107 5 2037 2042 20133848 90 Chen J Xie J Jiang Z Wang B Wang Y Hu X Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2 Oncogene 2011 30 42 4297 4306 21516121 91 Jung DW Kim WH Park SH A unique small molecule inhibitor of enolase clarifies its role in fundamental biological processes ACS Chem Biol 2013 8 6 1271 1282 23547795 92 Li X Tang S Wang Q-Q Identification of epigallocatechin-3-gallate as an inhibitor of phosphoglycerate mutase 1 Front Pharmacol 2017 8 1 9 28149278 93 Sujobert P Poulain L Paubelle E Co-activation of AMPK and mTORC1 induces cytotoxicity in acute myeloid leukemia Cell Rep 2015 11 9 1446 1457 26004183 94 Kung AL Zabludoff SD France DS Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway Cancer Cell 2004 6 1 33 43 15261140 95 Sapra P Kraft P Pastorino F Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects Angiogenesis 2011 14 3 245 253 21452059 96 Terzuoli E Puppo M Rapisarda A Aminoflavone, a ligand of the aryl hydrocarbon receptor (AhR), inhibits HIF-1α expression in an AhR-independent fashion Cancer Res 2011 70 17 6837 6848 97 Kubo T Maezawa N Osada M Katsumura S Funae Y Imaoka S Bisphenol A, an environmental endocrine-disrupting chemical, inhibits hypoxic response via degradation of hypoxia-inducible factor 1alpha (HIF-1alpha): structural requirement of bisphenol A for degradation of HIF-1alpha Biochem Biophys Res Commun 2004 318 4 1006 1011 15147973 98 Yeo E-J Chun Y-S Cho Y-S YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1 J Natl Cancer Inst 2003 95 7 516 525 12671019 99 Jones DT Harris AL Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding Mol Cancer Ther 2006 5 9 2193 2202 16985052 100 Narita T Yin S Gelin CF Identification of a novel small molecule HIF-1α translation inhibitor Clin Cancer Res 2009 15 19 6128 6136 19789328 101 Moreno-Manzano V Rodríguez-Jiménez FJ Aceña-Bonilla JL FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status J Biol Chem 2010 285 2 1333 1342 19897487 102 Welsh SJ Williams RR Birmingham A Newman DJ Kirkpatrick DL Powis G The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation Mol Cancer Ther 2003 2 3 235 243 12657718 103 Lee K Kang JE Park SK LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1α via upregulation of VHL in a colon cancer cell line Biochem Pharmacol 2010 80 7 982 989 20599784 104 Minegishi H Fukashiro S Ban HS Nakamura H Discovery of indenopyrazoles as a new class of hypoxia inducible factor (HIF)-1 inhibitors ACS Med Chem Lett 2013 4 2 297 301 24900662 105 Lee SH Jee JG Bae JS Liu KH Lee YM A group of novel HIF-1α inhibitors, glyceollins, blocks HIF-1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding J Cell Physiol 2015 230 4 853 862 25204544 106 Mabjeesh NJ Escuin D LaVallee TM 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Cancer Cell 2003 3 4 363 375 12726862 107 Kong D Park EJ Stephen AG Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity Cancer Res 2005 65 19 9047 9055 16204079 108 Nguyen TD Jin X Lee JH Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1 J Nat Prod 2007 70 7 1093 1097 17583950 109 Wallace EM Rizzi JP Han G A small-molecule antagonist of HIF2α is efficacious in preclinical models of renal cell carcinoma Cancer Res 2016 76 18 5491 5500 27635045 110 Chen W Hill H Christie A Targeting renal cell carcinoma with a HIF-2 antagonist Nature 2016 539 7627 112 117 27595394